News

Dr. Ruby Meierotto joins us to talk about breast density, breast cancer screening, and early breast cancer detection.

A secondary analysis of the pooled STEP-HFpEF and STEP-HFpEF DM trials showed the greatest improvements in those with the most weight loss at 52 weeks.

Dr. Mary Mitchell, chief of breast radiology at Saint Luke's, talks to KSHB about what dense breast tissue is and how it impacts your risk of developing breast cancer.

BBC News talked to Dr. Mikhail Kosiborod about new findings on the cardiovascular effects of semaglutide.

A new subanalysis presented by Dr. Mikhail Kosiborod shows benefits of semaglutide in patients with atrial fibrillation.

On average, survival benefits of CPR for cardiac arrest could be three times as high for white adults compared to Black adults and twice as high for men compared to women.

Semaglutide improves symptoms in both men and women who present with heart failure. When it comes to weight loss, however, the drug appears to benefit women much more than men.

Consumer Reports On Health talked to Dr. Bethany Austin and Austin Workman about strategies to improve quality of life for those living with heart failure.

The popular weight loss drug Wegovy seems to provide more health benefits for people who have diabetes and a common kind of heart failure than just helping take off the pounds, according to the results from the STEP HFpEF DM trial.

A new study led by Dr. Mikhail Kosiborod found patients with obesity-related heart failure and diabetes had a significant improvement in symptoms when taking semaglutide.